Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Pfizer

Pfizer and Moderna both face declines in coronavirus vaccine demand, and that should lower vaccine revenue. But both healthcare companies are set to launch new products that should boost growth.

Better Buy: Pfizer vs. Moderna

Moderna's mRNA Revolution: Unveiling A World Of Investment Potential Beyond COVID-19.

Moderna's mRNA Revolution: Unveiling A World Of Investment Potential Beyond COVID-19

Gilead Sciences

Humana

Johnson & Johnson

UnitedHealth Group

The United States healthcare system includes two sectors: public endeavors like Medicare and Medicaid and private health insurance companies. Healthcare stocks represent a significant section of the U.S. economy, with many medical companies included in indexes like the S&P 500.

6 Best Healthcare Stocks to Buy Right Now

Vertex Pharmaceuticals

The Federal Reserve's recent interest rate hikes mean banks charge much higher interest rates for loans. The interest on loans can be considered the price of borrowing more money.

3 Cash-Rich Biotech Stocks to Bet on for the Long Haul

Moderna's management expects revenue of between $8 billion and $15 billion by 2027. That's going to come primarily from COVID, RSV, and flu vaccine sales.

Is Moderna Setting Expectations Too High?

Moderna plans to use IBM's AI and quantum computing platforms in its mRNA research. The biotech's CEO aims for “breakthrough advances.

Can This AI Deal With IBM Be a Game-Changer for Moderna?

It's long been speculated that artificial intelligence (AI) and quantum computing could rapidly speed up advancements in many areas of science and technology, as both are able to parse massive amounts of information to gain pattern-based insights far faster than humans can. In the past, this has rarely come to fruition because it's difficult to direct that much computing power in a way that can yield the desired results.

Moderna: Critically Undervalued With a Promising Pipeline

CAMBRIDGE, MA / ACCESSWIRE / April 20, 2023 / Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, May 4, 2023 to report its first quarter 2023 financial results, and provide a corporate update.

Moderna to Report First Quarter 2023 Financial Results on Thursday, May 4, 2023

Moderna's partnership with IBM comes as the drugmaker navigates its post-pandemic boom driven by its mRNA Covid vaccine.

Moderna teams up with IBM to put AI, quantum computing to work on mRNA technology used in vaccines

Moderna's CEO said the partnership will allow the company to advance and accelerate its mRNA research and help it build a “quantum-ready workforce.”

Moderna Partners With IBM Hoping AI Can Help Develop More mRNA Medicine

Moderna's coronavirus vaccine business will lose steam in the next 12 months. The company is looking at steady progress with its pipeline.

Where Will Moderna Be in 1 Year?

Moderna invests in developing quantum computing skills and exploring the use of quantum computing in developing future mRNA medicines Agreement with IBM includes investments in generative AI to improve product design CAMBRIDGE, MA and ARMONK, NY / ACCESSWIRE / April 20, 2023 / Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and IBM (NYSE:IBM) today announced an agreement under which Moderna will explore next generation technologies including quantum computing and artificial intelligence to advance and accelerate mRNA research and science. "Since our inception, we have always strived to be at the forefront of cutting-edge technology, leveraging innovations to deliver the greatest possible impact to people through mRNA medicines," said Stéphane Bancel, Chief Executive Officer of Moderna.

Moderna and IBM to Explore Quantum Computing and Generative AI for mRNA Science

IBM and Moderna announced a new partnership today to explore the potential of generative AI and quantum computing.

IBM and Moderna explore quantum computing and generative AI with new partnership

Moderna reported positive data from its personalized cancer vaccine candidate. The biotech company aims to expand beyond its blockbuster coronavirus vaccine program.

Is Moderna About to Face the Same Challenge as Other Biotechs?

Moderna's coronavirus vaccine sales are on the decline -- and that has investors worrying about the future. Still, Moderna may not be a one-product company for very long.

Moderna Stock: Bear vs. Bull

BioNTech SE

To simplify the COVID-19 vaccination schedule for all individuals, the FDA authorizes using bivalent COVID-19 vaccines for all doses administered to individuals aged six years and older.

FDA Gives Nod for Using Bivalent Jab for All COVID Vaccinations

With low implied volatility right now, a bear put spread on Moderna is a viable strategy to profit on the downside. The post Bearish Option Trade For MRNA Stock appeared first on Investor's Business Daily.

Bearish Option Trade For MRNA Stock

Healthcare stocks for your Mid-April 2023 watchlist.

Top Stocks To Buy Now? 3 Healthcare Stocks To Know

Although the burden of the pandemic has eased substantially, the CDC says Covid continues to kill more than 1,300 people per week.

FDA authorizes additional omicron Covid shots for seniors and people with weak immune systems

Novavax

Moderna's experimental flu vaccine works well against influenza A strains but not against B strains (so far). This further solidifies Novavax's lead in the race to develop a combination COVID-19/flu vaccine.

Moderna's Flu Vaccine Struggles: Is Novavax Stock Now a Better Buy?

Roblox

Stock markets overcame weakness earlier in the day on Monday to finish modestly higher. Roblox reported business metrics for the month of March that raised concerns among shareholders about future growth.

These 2 Stocks Were Monday's Big Disappointments

Moderna disclosed positive results from a cancer trial over the weekend. However, results weren't better than already high expectations.

Why Moderna Stock Plunged Today

Moderna ( MRNA , Financial) emerged as one of the biggest beneficiaries of the pandemic after it developed one of the first Covid-19 vaccines. However, the momentum created by the pandemic is fading, and the problem for Moderna is that the vaccine was the company's big breakthrough - its first blockbuster.

Moderna Slumps as Vaccine Momentum Wanes

Detailed data from a mid-stage study shows that Moderna (MRNA)/Merck's personalized cancer vaccine candidate reduces the risk of recurrence/death.

Moderna (MRNA), Merck's Cancer Jab Delays Melanoma Recurrence

New data bolster the case for Moderna's experimental cancer treatment, but the path to turning it into a marketable product remains a long one.

News for Moderna Stock (MRNA)